Then you must have observed a significant increase in the number of prostate cancer
specimen received by you in recent years. It is expected that prostate cancer diagnosis and
intervention is likely to increase manifolds with greater health awareness and availability
of resources.
With the rapidly advancing field of Immuno-pathology, Molecular diagnostics and
therapeutics, a modern-day pathologist is expected to be not only well versed in the
histopathological techniques but also need to keep pace with the changes happening in
the clinical application of the information provided by them through the pathology report.
Recent changes suggested in Gleason grade grouping system exemplifies a greater push
toward making the reporting system more clinically meaningful and outcome based. At no
time in the history of providing health care has the clinician-pathologist collaboration been
more important. It behoves both groups (Clinicians and pathologists) to become familiar
with the role each plays and the potential for collaboration to change the face of health
services.
This meeting aims to provide a concise update on the use of immuno-histochemistry in
prostate biopsy, handling and reporting of Radical prostatectomy specimen, refinement of
the histological criteria (update in WHO 2016, AJCC 2016) and the new proposal to group
Gleason scores into clinically meaningful "grade groups".
Come and join us and learn
Course Directors:
Course Co-Director:
Dr Rajiv Yadav & Dr Manav Suryavanshi
Dr Varun Mittal